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Limited information is available regarding AmpC -lactamase (ABL)-producing Enterobac-
teriaceae  compared to extended-spectrum -lactamase-producing enterobacteria. Since
ABL-producing  organisms are often resistant to multiple antimicrobial agents, therapeu-
tic  options against these pathogens are limited. Among 230 clinical Enterobacteriaceae
isolates, 64 (27.8%) were found to produce ABL in our study. Escherichia coli (83.9%) was a
predominant pathogen, followed by Citrobacter freundii (5.2%). A signiﬁcant proportion of
ABL-producing isolates (81.3%) were found to be multidrug resistant against commonly used
antibiotics. Univariate analysis showed that prior history of taking antibiotics (odds ratio
[OR],  5.278; conﬁdence interval [CI], 2.838–9.817; p < 0.001) and being inpatients (OR, 4.587;CI,  2.132–9.9; p < 0.001) were associated with ABL positivity. Regular antimicrobial resistance
surveillance  for ABL-producing Enterobacteriaceae is warranted for proper antimicrobial
treatment  strategy and policy making due to ABL-positive infections.
salmonella), and the conjugational transferability of ABL-
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDThe emergence of AmpC -lactamase (ABL)-producing Entero-
bacteriaceae is now a major worldwide problem due to their
features  of non-beta-lactam coresistance and high poten-
tial  to transfer the drug resistance features horizontally to
other  Enterobacteriaceae members via their transmissible
plasmid(s).1 In recent years, there are increasing reports
about the dissemination of ABL-producing Enterobacteria-
ceae from hospital to community in different countries.
However, little is known about the occurrence of ABL-
producing Enterobacteriaceae in Nepal, although high rates of
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Este é um artigo Open Access sob a licençaprevalence have been reported in neighbouring countries, up
to  36.5% in India,2 35.6% in Pakistan3 and 26.2% in China.4 We
conducted  a prospective study in a tertiary care hospital of
Nepal,  located at capital Kathmandu, with the aim to deter-
mine  the prevalence, etiology and antimicrobial susceptibility
of  ABL-producing Enterobacteriaceae (other than typhoidalvan University, Kirtipur, Kathmandu, Nepal.
positive  phenotypes in Escherichia coli (E. coli). Additionally,
the present study also highlights the clinical characteris-
tics of patients infected with ABL-positive Enterobacteriaceae
 de CC BY-NC-ND
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nd identiﬁed some of the risk factors for ABL-positive
nfections.
During a six-month period of 2007, a total of 230 consec-
tive isolates of Enterobacteriaceae from the same number
f  non-repeat patients were collected by Kathmandu Model
ospital  Laboratory from different clinical specimens, includ-
ng  urine, swabs and ﬂuids. All suspected symptomatic
atients with culture-proven diagnosis of Enterobacteriaceae
or the collected samples from the suspected anatomical
ites of infections were considered to acquire Enterobacte-
iaceae infections. Each of the included 230 patients was
nterviewed directly using a structured questionnaire to col-
ect  the data about patient’s demographics, patient’s category
outpatient or inpatient), prior antibiotic exposure, history of
rinary  tract infection (UTI) and presence of any underlying
llnesses (diabetes mellitus, malignancies, liver disease and
enal  dysfunction) or comorbidities (recent surgical opera-
ions  in the last six months, taking immunosuppressant, using
ndwelling  urinary catheter or other mechanical devices).
ritten informed consents were obtained from all patients
rior  to inclusion in the study. This study was  approved by the
thics  and Research Committee of Kathmandu Model Hospi-
al.
All  the received clinical samples were collected and
rocessed by standard microbiological methods.5 Following
ollection the sample was  transferred to the laboratory imme-
iately  and inoculated on blood agar and McConkey agar.
solates  were  identiﬁed based upon colonial characteristics
nd conventional biochemical tests.5 Antimicrobial suscep-
ibility  patterns were  determined by disk diffusion method
sing  commercial antibiotic disks (Oxoid Ltd., Basingstoke,
K).6 Identiﬁcation of isolates of Enterobacter cloacae, Enterobac-
er  aerogenes and Citrobacter spp. were judged as ABL producers,
s  they are known for chromosomal ABL producers and
ften  produce ABL constitutively.1,7 The screening for other
resumptive ABL-producers in the possibility of presence
f  extended-spectrum -lactamase (ESBL) was  improved by
he  criteria of cefoxitin (30 g) insusceptibility, positivity for
SBL  screening and negative result for ESBL conﬁrmation.
or the assessment of ESBL production, double-disk synergy
est  using a disk containing of amoxicillin/clavulanic acid
20/10  g) was  performed using positive and negative control
trains  for ESBL production.8 The phenotypic conﬁrmation of
BL-positive  was  determined by AmpC disk test.9 The AmpC
isk  containing a 1:1 mixture of saline and 100× Tris–EDTA
olution was  made in-house according to Black et al.9 The
rocedure of AmpC disk testing was  followed according to
lack  et al.9 In brief, a cefoxitin disk (30 g) was  placed on
he  lawn  of E. coli ATCC 25922 on Mueller-Hinton agar plate.
ust  before the use, AmpC disk was  moistened with 20 L of
aline  and several colonies of a test organism were applied
o  a disk and then placed to almost touching a cefoxitin disk
n  inoculated surface of agar with the face of inoculated disk
n  contact with the agar surface. After incubation overnight,
he  ABL production was  identiﬁed by the presence of either
n  indentation or a ﬂattening of the zone of inhibition. We
xcluded  the isolates of Salmonella enterica serotype Typhi and
aratyphi  A because none of them were found resistant to
nd  and 3rd generation cephalosporins at the time of study,
nd  it was  felt that including them could misestimate the3;1  7(2):256–259  257
prevalence  of ABL-producing isolates among Enterobacteria-
ceae.
The ABL-positive E. coli isolates which were  susceptible
for streptomycin were screened and selected for conjuga-
tion  study to evaluate the horizontal transfer of ABL-positive
phenotypes. Evidence of the similar size of intact plasmid(s)
between donors and transconjugants, the resistant features to
cefoxitin, cefatzidime (30 g), cephotaxime (30 g) and amox-
icillin/clavulanic acid by transconjugants, and the positive
result  of AmpC disk test by transconjugants was  judged
as  transferable ABL-positive phenotypes. The plasmid was
extracted  and puriﬁed using commercial kits (Qiagen GmbH,
Hilden,  Germany) according to the manufacturer’s instruc-
tions.  Conjugation was done as described by Baral et al.,10
using plasmid free E. coli HB 101 (F−S+lac−) as the recipi-
ent strain. Transconjugants were selected on MacConkey agar
supplemented  with streptomycin (100 g/mL) and cefoxitin
(20  g/mL).
Statistical  analyses were  performed using SPSS (version
18.0,  SPSS Inc., Chicago, IL) software package. Categorical vari-
ables  were analyzed by Chi-square test or Fisher’s exact test,
as  appropriate. Univariate analysis was performed for calcu-
lation  of odds ratio (OR) with 95% conﬁdence interval (CI) for
potential  risk factors. A p-value of less than 0.05 was  consid-
ered  statistically signiﬁcant.
A  total of 230 Enterobacteriaceae isolates were  recovered
from 1, 503 clinical specimens during 6-month study period.
Out  of the total isolates, E. coli (83.9%) was  the predom-
inant pathogen, followed by Citrobacter freundii (5.2%) and
Enterobacter spp. (3%). Totally 64 (27.8%) ABL-producing Entero-
bacteriaceae  were observed in 230 Enterobacteriaceae isolates,
among  them E. coli (59.7%) was  the most common organism,
followed by C. freundii (18.8%). The mean age of the patients
harbouring ABL-producing Enterobacteriaceae was  49.3 years
(range  2–92 years). None of the isolates of Proteus spp. and Kleb-
siella  spp. were shown to produce ABL in our study. Similar
to  our study, high occurrence rates of ABL-producing Entero-
bacteriaceae were reported in other Asian countries.2,4,11
The majority of ABL-producers were found to exhibit high
rates  of resistance to commonly used antibiotics as shown
in  Table 1. Speciﬁcally, high rates of resistance observed to
ﬂuoroquinolones (67.2% resistance to ciproﬂoxacin, 59.4% to
norﬂoxacin, 54.7% to oﬂoxacin), aminoglycosides (48.4% resis-
tance  to gentamicin) and nitrofurantoin (20.3% resistance)
are  most worrisome (Table 1), because these drugs can be
bought  even by low-income class of Nepalese people and
are  easily available in different pharmacy counters across
Nepal.  Two ABL-producing C. freundii were found resistant to
meropenem, while none of the isolates was found resistant
to  imipenem. It is not uncommon to ﬁnd carbapenem resis-
tance  among ABL-producing isolates.12 Comparatively, rate
of  meropenem insusceptibility (0.87% resistance in Entero-
bacteriaceae) observed in our study is lower than a report
from  India (22.16% resistance among Gram-negative bacterial
pathogens).13 As we expected, a signiﬁcant proportion of ABL-
producing  isolates (81.3%) showed resistance to ≥3 different
classes  of antibiotics, deﬁned as multidrug resistant (MDR).
Out  of 33 ABL-producing E. coli isolates, 72.7% (n = 24)
exhibited transferable ABL-positive phenotypes as revealed
by  conjugation study. The majority of ABL-producing donor
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Table 1 – Antimicrobial resistance (%) by AmpC -lactamase (ABL)-positive and -negative Enterobacteriaceae isolates.
Antibiotic ABL-positive (n = 64) ABL-negative (n = 166) p-value
Trimethoprim-sulfamethoxazole 78.1 28.9 <0.001
Nitrofurantoin 20.3 6.6 0.016
Ciproﬂoxacin 67.2 19.9 <0.001
Norﬂoxacin 59.4 16.3 <0.001
Oﬂoxacin 54.7 15.7 <0.001
Amikacin 18.8 1.8 <0.001
Chloramphenicol 20.3 6.6 0.002
Gentamicin 48.4 60.2 0.105
Meropenem 3.1 
Imipenem 0 
isolates harbored multiple plasmids most commonly of size
32.5  kb and 38 kb, whereas plasmid of size 32.5 kb was the
most  common plasmid among the ABL-producing transcon-
jugants.  ABL positivity with the MDR  pattern (amoxicillin-,
ciproﬂoxacin-, ceﬁxime-, trimethoprim-sulfamethoxazole-,
oﬂoxacin-, and norﬂoxacin-resistance) was  found most
commonly (78%) to be transferred to recipient strain by
conjugation. The high prevalence rate of transferable ABL-
positive  phenotypes observed in our study may  indicate an
increased  transmission rate of drug resistant plasmids that
have  acquired genes for AmpC enzymes among pathogenic
Enterobacteriaceae isolates, which can consequently make
the  bacteria which are known for lacking or poorly express-
ing  chromosomal AmpC -lactamase gene, such as in E. coli
and  Klebsiella pneumoniae.1 The clinical characteristics of
230  patients infected with Enterobacteriaceae are shown in
Table  2. Univariate analysis revealed that prior use of antibi-
otic  in the last six months (OR, 5.278; CI, 2.838–9.817; p < 0.001)
and  being inpatient (OR, 4.587; CI, 2.132–9.9; p < 0.001) were
associated with ABL-positive infections (Table 2). It is not sur-
prising  to mention that in Nepal there is extensive practice of
irrational  antibiotic use, especially by self-medication because
drugs  are easily accessible in the pharmacy counters with-
out  prescription, and this may  create the selection pressure
to  emerge ABL-positive MDR  pathogens as we observed in the
Table 2 – Univariate analysis of AmpC -lactamase (ABL) positi
Potential risk factors Total isolatesn = 230 (%) 
Age of patient
≤30  years 100 (43.5) 
31–60 years 74 (32.2) 
>60 years 56 (24.3) 
Gender
Male 54 (23.5) 
Female 176 (76.5) 
Presence of any underlying illnesses
and/or  comorbidities
85(37)  
Prior history of UTI (last one year) 90 (34.3) 
Prior use of antibiotic (last six month) 74 (32.2) 
For cases with UTI 202 (87.8) 
Category of patient
Inpatient  33 (14.3) 
Outpatient 197 (85.7) 
UTI, urinary tract infection.0 0.077
0
present  study. However, further molecular study involving the
isolates  from different regions of Nepal is needed to conﬁrm
such  situation in Nepal. The high frequency of ABL-producing
Enterobacteriaceae infections (57.6%) among the inpatients
implies  the extensive dissemination of ABL-producing bacte-
ria  in hospital environments (Table 2). An increased rate of
occurrence  of ABL-producers (63.4%) was also observed among
nosocomial  isolates of E. coli and K. pneumoniae in a recent
report  from India.14 It may  indirectly suggest that the contrib-
utors  that led to the emergence and spread of ABL-producing
Enterobacteriaceae among the hospitalized patients of both
countries  have a common mechanism.
In conclusion, we observed a high prevalence rate of ABL-
producing Enterobacteriaceae among Nepalese patients and
the  majority of them showed increased rates of antibiotic
resistance. To our knowledge, this is among the ﬁrst reports
to  describe about clinical and microbiological characteris-
tics of ABL-producing Enterobacteriaceae, and documenting
plasmid-mediated transfer of ABL-positive phenotypes of
E.  coli from clinical isolates of Nepal. Our study not only
strongly suggests the dissemination of ABL-producing Entero-
bacteriaceae  in our locality, but also among the patients of all
geographical  locations of Nepal, because many  people from
outside  of Kathmandu regularly visit our hospital seeking
for  better treatment facility. Regular nationwide antimicrobial
vity among pathogenic Enterobacteriaceae isolates.
ABL-positive isolatesn = 64 (%) OR (CI 95%) p-value
23 (23) 0.648 (0.358–1.175) 0.152
23 (31.1) 1.265 (0.689–2.323) 0.448
18 (32.1) 1.318 (0.685–2.536) 0.407
18 (33.3) 1.413 (0.732–2.729) 0.302
46 (26.1)
30 (35.3) 1.781 (0.989–3.205) 0.053
26 (28.9) 1.09 (0.605–1.965) 0.773
38 (51.4) 5.278 (2.838–9.817) <0.001
54 (26.7) 0.657 (0.285–1.511) 0.32
19 (57.6) 4.587 (2.132–9.9) <0.001
45 (22.8)
 2 0 1 
r
w
w
C
A
r
1
1
1
1
1b r a z j i n f e c t d i s .
esistance surveillance incorporating the detection of ABLs is
arranted in order to restrict the possible burden associated
ith  ABL-positive Enterobacteriaceae infections.
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